Following are the latest news and information resources for the various mental health topics that we cover. We hope you will find the news educational and the links in the resources section useful in helping you to get even more in-depth data.
Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as one of the most common mental disorders in the world (Dobson and Dozois, 2008). MDD is a type of mood disorder characterized by persistent feelings of sadness, anger, loss, or frustration that can last from days to months and alternates with episodes of wellness (MedlinePlus, 2013). Little is known about the etiology of MDD; however, research suggests that chemical changes in the brain may potentially increase the risk of MDD (NHS, 2012).
The prevalence of MDD is high in both developed and developing countries, with approximately 350 million people living with the condition worldwide as of 2012. Globally, the total lifetime prevalence of MDD according to the recent World Mental Health (WMH) surveys varies from 6.6% in Japan to 21.0% in France, whereas the total 12-month period prevalence of MDD varies from 2.2% in Japan to 10.4% in Brazil (Bromet et al., 2011; Lepine and Briley, 2011).
MDD is a highly debilitating condition that is associated with substantial morbidity and an enormous social and economic burden. The condition affects the thoughts, feelings, behavior, and physical health of an individual, leading to a range of psychological, physical, and social problems. According to the World Health Organization (WHO), depression is one of the major contributors to the global burden of disease (WHO, 2012). In 2000, MDD was the third leading cause of disability, accounting for 4.3% of Disability-Adjusted Life Years (DALYs) worldwide, and is predicted to become the leading cause of disability by 2030 (Murray and Lopez, 1996; Ustun et al., 2004; WHO, 2012). Although MDD is treatable and manageable, it can lead to serious consequences, including suicide, if left untreated (MedlinePlus, 2013; NHS, 2012).
This report provides an overview of the risk factors and the global and historical trends for MDD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). In addition, the report includes a 10-year epidemiological forecast (2013-2023) for the total prevalent cases of MDD in these markets, segmented by age (ages >=20 years) and sex. To construct the 10-year epidemiological forecast for the total prevalent cases of MDD in the 8MM, GlobalData epidemiologists selected only country-specific studies that provided the total prevalence of MDD based on the American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria, using the Composite International Diagnostic Interview (CIDI) version 3.0 as the diagnostic instrument. The CIDI is a comprehensive and fully-standardized diagnostic interview tool designed to diagnose MDD according to the DSM-IV criteria (Dobson and Dozois, 2008).
Epidemiologists forecast that the total prevalent cases of MDD in the 8MM will grow by 4.0% over the next decade, from 31,798,832 total prevalent cases in 2013 to 33,083,108 total prevalent cases in 2023. GlobalData epidemiologists attribute the growth in the total prevalent cases of MDD in the 8MM to changing population demographics in the respective markets, rather than to an actual increase in the prevalence of MDD in these markets. http://www.soundmindz.org/anti-depression-appRead article >>
A study published in the March 2014 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that the majority of youth with moderate to severe anxiety disorders responded well to acute treatment with cognitive behavioral therapy (CBT), medication (sertraline), or a combination of both. They maintained positive treatment response over a 6 month follow-up period with the help of monthly booster sessions.
As part of the NIMH Child/Adolescent Anxiety Multimodal Study (CAMS), a group of researchers led by Dr. John Piacentini of the UCLA Semel Institute for Neuroscience and Human Behavior, followed 412 children and adolescents ages 7-17 after they completed 12 weeks of acute treatment. Treatment responders were offered 6 additional monthly booster sessions, with those initially on medication continuing this treatment; all youth, regardless of status at week 12, were re-evaluated 3 and 6 months later by trained clinicians. Twenty-seven percent of study participants also reported receiving outside (e.g. nonstudy) psychotherapy and/or medication for mental health symptoms over the 6 month follow-up period.
The study found that over 80% of youth rated as positive responders to one of the three CAMS treatments at Week 12 were also rated as responders at both the 3 and 6 month follow-up evaluations. Conversely, only 5% of youth who received combined CBT plus sertraline, and 15-16% of youth receiving either CBT-only or sertraline-only, failed to achieve responder status at any time during the study. Youth in the combined CBT+sertraline group showed greater treatment benefits on some but not all outcome measures and used less nonstudy treatments than those in the CBT-only and sertraline-only groups.
Collectively, anxiety disorders are the most common mental disorders in children and adolescents. Often overlooked, severe anxiety can significantly impair children's school, social, and family functioning, and if untreated, can increase the risk of depression, alcohol and substance abuse, and occupational difficulties in adulthood.
CAMS is the largest randomized controlled comparative treatment trial for child/adolescent anxiety disorders ever conducted. Participants were recruited at six regionally dispersed sites throughout the United States (UCLA, Duke University, Columbia University/New York University, Johns Hopkins University, Temple University, and the Western Psychiatric Institute and Clinics/University of Pittsburgh) and randomly assigned to 12 weeks of treatment with cognitive behavioral therapy (Coping cat), the selective serotonin reuptake-inhibiting [SSRI] medication sertraline, cognitive behavioral therapy combined with sertraline, or pill placebo. All participants had moderate to severe separation anxiety disorder, generalized anxiety disorder or social phobia, with most having multiple anxiety or other mental health disorders.
"The results of this study provide further evidence of the benefits of cognitive behavioral therapy and SSRI medication, alone or in combination, for treating clinically significant anxiety in children and adolescents," said Dr. Piacentini. "A separate project by the CAMS researchers is now gathering information on how study participants are doing up to 10 years after study participation." http://www.soundmindz.org/anti-anxiety-appRead article >>
Lowering the brain's pH may treat anxiety disorders, according to a new study.
The latest research on animals reveals that increasing acidity in the brain's emotional control center reduces anxiety.
Researchers said the latest findings point to a new target for treating anxiety disorders, which are characterized by the lack of ability to control feelings of fear and uncertainty. Previous studies have linked anxiety disorders to heightened activity in the basolateral amygdala (BLA), a brain region that plays a central role in emotional behavior.
Researchers said that many cells in the basolateral amygdala posses acid-sensing ion channels called ASIC1a, which respond to pH changes in the environment outside of the cell.
Experiments revealed that activating these acid-sensing ion channels decreased the activity of nearby cells and reduced anxiety-like behavior in animals. Researchers said the findings supports previous evidence linking ASIC1a to anxiety.
For the study, researchers soaked BLA cells in an acidic solution in the laboratory and measured the signals sent to nearby cells. Researchers found that increasing the acidity or lowering the pH of the solution decreased activity of cells in the BLA.
The study also found that activating ASIC1a impacted behavior. Researchers said that rats displayed more anxiety-like behavior when they were given a drug that blocks ASIC1a directly into the BLA. However, rats given a drug that increased the activity of ASIC1a channels in the BLA showed less anxiety-like behavior.
"Our study emphasizes the importance of identifying and elucidating mechanisms involved in the regulation of brain function for the development of more efficacious therapies for treating psychiatric and neurological illnesses," lead researcher Maria Braga, DDS, PhD, of the Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, said in a news release.
"These findings suggest that activating these channels, specifically in fear-related areas such as the amygdala, may be a key to regulating anxiety," Anantha Shekhar, MD, PhD, who studies panic disorders at Indiana University and was not involved in this study, said in a news release. "Developing specific drugs that can stimulate these channels could provide a new way to treat anxiety and fear disorders such a post-traumatic stress and panic disorders."
Researchers noted "more research is needed to understand the roles that ASIC1a channels play in the brain."Read article >>
You've seen the TV commercials, the person in black and white and sad while they watch their friends and family in color happy as can be? Then the sad individual gets help, sees the world in color and has a dog run into frame to play with them, or they are suddenly on the couch petting their beloved cat. Well, there's a reason for that, pets can help individuals with depression/illnesses/anxiety.
"Pets offer an unconditional love that can be very helpful to people with depression," says Ian Cook, MD, a psychiatrist and director of the Depression Research and Clinic Program at UCLA.
Depression affects millions of individuals in the USA alone. A lot of people reading this suffer from some form or know someone who does. A pet might not be right for everyone, so don't just show up with a pet one day for someone you know with depression.
The first thought that enters many heads is "I can barely take care of myself, a pet would be a mistake." Well, with great pets, comes great responsibility. Depression studies have shown responsibility promotes mental health. "Taking care of a pet can help give you a sense of your own value and importance," says Cook. It will remind you that you are capable -- that you can do more than you might think." You still may be arguing that you can't even get out of bed or off the couch, well that won't fly (unless you get a bird, in which case let it fly around). Pets add routine to your life, you want be able to stay in bed till 2 pm or lay on the couch till 11:30, pets have a schedule and they will help you schedule your life again. You'll have to get up to feed them, let them out, play with them, walk them, feed them again. Pets get you off your butt and moving again.
Depression has a strongest weapon, and that weapon is isolation. It will pull you back from your friends and family, you'll dodge calls/texts/snapchats/IM all of it. Leaving you to question all your thoughts alone, that is when depression strikes hardest. Pets offer the opposite of isolation, they bring companionship. A dog will never leave you alone, in a good way. My dogs run up to me all day throwing toys at me, laying on me, whine until I pick them up. I'm never alone, and I love my pets for that. I have woken up at 3 am to one of my dogs throwing a football at my head, meaning its play time now. Having a pet means you're never alone, even when you shut the door to go to the bathroom in peace, your pet will barge in "You watch me go, why can't I watch you go?"
Pets give us routine, keeping us active, dogs have the added benefit of being brought on walks, or to dog parks. This exercise of taking your pet out promotes physical activity which in turn promotes mental and physical health. Walks help you lose weight, get you out of your depressing house which you've been cooped up in for far too long and also lets your pet relieve themselves with no shame. Say you're walking your dog or bring them to the dog park, well there's a good chance someone's going to come up to you to ask to pet your dog or ask what kind of breed they are, your dog will encourage you to interact socially. You may be shy or anxious or still feel alone, but guaranteed your dog will get attention and thus bring the interaction to you. So long isolation, hello social butterfly wonder dog. You may hate talking about yourself or not care what others say but pet owners love talking about their pets like children, and it's safe to say if you have a pet you like pets in general, so you'll go ahead and converse about them. Let your pet shine.
If I'm not petting one dog I'm petting the other, if I'm not scratching a friends cat behind the ears them I'm scratching another. Studies show that people feel better when they have physical contact with others. Petting a cat and listening to them purr soothes you, rubbing your dogs belly and watching their leg kick also relaxes you. You're no longer sitting in the house just lying there, you have someone to touch, to talk to, to interact with.
Finally, there's laughter, endless laughter. Depressions got you down well your pet with 100% certainty will make you laugh. I've had my dogs fart on me when I've gone to pick them up and the sound scares them so they run away, one of them fell off my bed in the middle of the night while dreaming and got right back up with his tail wagging like it was the best dream ever. Depression makes you think about everything that has gone wrong and everything that can go wrong over and over again until you can take it no more. These little moments with pets that make you laugh make a world of difference. You may laugh as your cat chases a laser pointer around your house trying to catch the blasted red dot, or as they randomly fall asleep anywhere they like, like upside down on top of a loaf of a bread, the point being that though they are pets they have more empathy than we could ever dream.
The hardest step is getting up and seeking help and once you do that, take your pet for a walk or pet them, anything to get your mind on track a little more. Pets may not cure depression, but they certainly can help calm you.Read article >>
For a long time now, scientists have been aware of a link between chronic stress and developing mental illness in later life. Now, a new study has tracked the physical changes in parts of the brain that occur due to chronic stress, giving insight into just why stress might create mental health issues and pointing to how we might prevent this from happening.
The research, carried out by a team at the University of California, Berkeley, and published in the journal Molecular Psychiatry, has shown that chronic stress actually causes physiological changes in the brain.
It’s long been known that people with stress-related illnesses, like post-traumatic stress disorder (PTSD), exhibit very particular changes in different brain regions. In particular, in the amount of gray matter versus white matter they have. However, until now the reasons behind this have remained a mystery.
In a series of experiments, the UC Berkeley team were able to track how chronic stress causes the production of more myelin-producing cells, which would increase the white matter in some areas of the brain. Due to the fact that white matter functions to create connections in the brain, this research suggests that the overproduction of myelin-creating cells might disrupt the fine balance the brain needs for timing the communications between different regions.
“We studied only one part of the brain, the hippocampus, but our findings could provide insight into how white matter is changing in conditions such as schizophrenia, autism, depression, suicide, ADHD and PTSD,” Daniela Kaufer, UC Berkeley associate professor of integrative biology and lead researcher in this study, is quoted as saying.
To explain how this increased connectivity might affect people and cause mental health problems, Kaufer uses the example of people with PTSD, which is an anxiety disorder that can be crippling in its severity. It is perhaps most commonly associated with former military personnel.
Kaufer hypothesizes that the traumatic events the sufferer has endured increase the number of connections between regions of the brain like the hippocampus, which regulates memory and emotion, with regions like the amygdala, which is at least partially responsible for the so-called “fight or flight” response. In turn, this would lead to difficulties regulating things like anxiety, especially when other regions of the brain that might moderate our responses have fewer of those same connections. This, Kaufer says, leads to an emotional response that is out of proportion with the reality of the situation, producing uncontrollable panic responses.
To be clear, this research is ongoing and the hypothesis needs to be subjected to widespread human tests, but the basic science behind it appears sound. As well as testing this particular line of thought, the researchers also want to look at chronic stress and what physiological impact early life trauma has on later developing mental health problems. That’s because various research has already found a connection between trauma in childhood and later developing mental health issues.
The research also emphasizes the possible advantages of early intervention so that chronic stress-induced changes in the brain are minimized and the fallout, particularly in young children, can be managed. In turn, it is hoped that early intervention strategies might prevent people developing mood disorders in later life, though this remains a subject of study.
All in all, the research has been welcomed as an important small step into gaining insight into what might be happening at the smallest physiological levels in our brains and how the body reacts to chronic stress, and its potential for helping us understand the complexity of mood and anxiety disorders is encouraging for anyone who, like myself, must deal with a mental health problem.Read article >>
Risk of depression is lower in menopausal women after their final menstrual period (FMP) but a history of depression increases the risk of depressive symptoms both before and after menopause, according to a new study from researchers at thePerelman School of Medicine at the University of Pennsylvania. The study, published in this week’s issue ofJAMA Psychiatry, shows that the FMP is pivotal in the overall pattern of decreasing the risk of depressive symptoms in middle-aged women, with higher risk before and lower risk after the final menstruation.
“Some women begin to experience depressive symptoms as they approach menopause and, although only a small percentage experience difficulty or changes in mood around that time, it’s important that health care providers be able to tell their patients what to expect,” said lead authorEllen Freeman, PhD, research professor of Obstetrics and Gynecology at Penn Medicine. “What this study shows is that in general, women can expect the risk of depressive symptoms to decrease in the second year after their final menstrual period. It is important to note that most women who experience depression during menopause do so before the transition as well. For this group, there may be some decrease postmenopause, but the risk for recurring episodes remains high.”
Previous research has shown an increased risk of depression associated with a woman’s transition to menopause, but until now the risk of depression in the first years following the transition has not been examined. In an effort to identify changes in the risk of depression and the link between a history of depression prior to menopause, researchers examined depressive symptoms during a 14-year period in women who were premenopausal at baseline and then progressed through menopause.
Results of the study show scores on a depression scale were higher 10 years prior to the final menstrual period, and decreased for up to eight years after. Subjects who experienced their first symptoms of depression as they approached menopause had a significantly lower risk of recurring symptoms the second year after their final menstrual period. However, among women with a history of depression, the likelihood of continued symptoms of depression was 13 times higher overall and 8 times higher after menopause compared to women with no history of depression.
“Studies show that as a woman approaches menopause changes in reproductive hormones contribute to an increased risk of depression, so it’s not surprising that after menopause the risk of depression decreases,” said Freeman. “However, understanding the risk of depression for these patients is important because of its association with other health conditions such as cardiovascular disease, metabolic syndrome and osteoporosis.”
The authors suggest a clinical review of depressive symptoms is necessary to provide treatment when symptoms are debilitating, and to evaluate the effect of depression on other disorders. Depending on a patient’s history of depressive symptoms, antidepressant or psychotherapy may be appropriate.
Other study authors from Penn include Mary D. Sammel, ScD, David W. Boorman, MS, and Rongmei Zhang, PhD.
The study was supported by the National Institutes of Health (RO1 AG12745; RR024134).Read article >>
University of Sydneystudy is looking into the effectiveness of omega-3 supplements and the antidepressant, sertraline, in reducing depressive symptoms and cognitive decline in older people, in a bid to prevent the onset of depression and dementia in later life.
The research, led by the University'sBrain and Mind Research Institute (BMRI),is evaluating the effects of the two substances in preventing degenerative changes in brain matter, based on the abundance of literature linking depression with changes in the brain's blood vessels, oxidative stress and with other factors that are known to be protective for the brain.
Depression and anxiety affects three million Australians every year, and between 10 and 15 percent of older people experience depression, while around 10 per cent experience anxiety. Rates of depression among people living in residential aged-care facilities are believed to be much higher, at around 35 per cent.
Alarmingly, one in 10 Australians aged 65 and over had dementia in 2011, while three in 10 Australians aged 85 and over had dementia in 2011. An estimated 322,000 Australians were estimated to have dementia in 2013. Based on projections of population ageing and growth, the number of people with dementia will reach almost 400,000 by 2020, and around 900,000 by 2050.
Study lead,Associate Professor Sharon Naismith, said the work was one of very few projects in the world looking into ways to prevent onset of depression and dementia in older populations.
"Over the last decade, our BMRI team has demonstrated that the cognitive, brain scanning (MRIs) and clinical features of late-life depression are linked with brain disease and cognitive decline," she said.
"These changes are in turn linked to disability, functional decline and progression to dementia.
"Importantly, major depression in older people can now be detected earlier, through the tracking of depressive symptoms, and there is recognition internationally that prevention trials are now urgently warranted."
The study utilizes the "Beyond Ageing cohort", a group of older persons with depressive symptoms who are scanned regularly through MRIs. The first group of 60 older adults 'at-risk' of depression were randomized to receive either omega 3 supplementation or placebo for 12-weeks.
Participants underwent MRI brain imaging, medical and neuropsychological assessments at the start of the trial and again after 12-weeks of supplementation. The results showed that participants taking the placebo had greater brain matter changes (specifically glutathione/creatine ratio in the thalamus) after the 12-week intervention, which, correlated with increased severity of depressive symptoms.
"Our findings offer promise for the prevention of depression in older people and the brain changes leading to depression, cognitive decline and dementia," Associate Professor Naismith said.
"We are not always sure what brain white matter change is due to but they can be due to vascular damage (from hypertension, high cholesterol, heart disease) or could instead be inflammatory. The presence of such changes on MRI is commonly seen in people who have depression in later life.
"We hope that the use of fish oils will stabilize this inflammation and support the brain vascular system, thereby also preventing depression and cognitive decline." The trial will conclude in 2016.
Chief Investigators:A/Prof Sharon Naismith, Prof Helen Christensen, Prof Ian Hickie.
Funding:The Beyond Ageing Project Grant is being funded by an National Health and Medical Council (NHMRC) grant and the BUPA Foundation.Read article >>
Total sleep deprivation and light therapy relieve depression in bipolar patients but do not improve overall cognitive function, according to an Italian study published in the Journal of Affective Disorders.
In addition, bipolar patients "do not experience the well-known worsening of performance observed in healthy controls after sleep loss," said Sara Poletti, Ph.D., of the Scientific Institute and University Vita-Salute San Raffaele Turro, Milan, and her associates (J. Affect. Disord. 2014;156:144-9 [doi:10.1016/j.jad.2013.11.023]).
The investigators administered the Brief Assessment of Cognition in Schizophrenia (BACS) to 100 depressed bipolar I patients (DSM-IV) and 100 healthy controls, and then retested 42 subjects with bipolar disorder who underwent total sleep deprivation (TSD) and light therapy (LT), during which they were kept awake for three 36-hour periods over the course of a week, with bright lights shone on them for 30 minutes at 3 a.m. on TSD nights and in the morning after recovery sleep. The Hamilton Depression Rating Scale (HDRS) was administered to assess depression.
The mean age was 47 years in the bipolar group and 44 years in the control group. Both groups were made up of a majority of women. A quarter of the patients with bipolar disorder reported previous psychotic symptoms. Most of the TSD/LT patients were taking lithium, and some were taking other mood stabilizers, benzodiazepines, and antidepressants.
As expected from previous investigations, the 100 bipolar patients had significantly lower baseline cognitive function scores, showing impairment in verbal memory, working memory (digit sequencing), psychomotor coordination (token motor task), verbal fluency, selective attention (symbol coding), and executive function (Wisconsin Card Sorting Test).
Also in keeping with past studies, TSD/LT treatment caused an overall significant decrease in HDRS scores: 31 of the patients with bipolar (74%) achieved the strict remission criterion of HDRS score of less than 8 at day 7 and could be rated as full responders to treatment.
Regarding cognitive function, TSD and light therapy "showed a significant difference only for symbol coding (P less than 0.004). No significant differences were found for the remaining variables," Dr. Poletti and her associates said.
"Although most of the patients responded to TSD treatment reporting a clinical improvement of depressive symptomatology, cognitive deficits persisted in almost each function. The only improvement we observed was in symbol coding, confirming a positive effect of TSD on speed-of-information processing in bipolar patients," they wrote.
Also "in agreement with the literature, we found that as medication load decreases, cognitive performance improves. However, medication effects alone are not likely to fully account for the deficits described in these patients. We can hypothesize that TSD and LT act on cognitive functions through their effect on brain structures and neurotransmitter system[s]. Studies are needed to understand if remediation strategies such as those used for schizophrenia treatment could be introduced for bipolar patients," the investigators said.
Among the study limitations is that "the use and reporting of medications varied between patients, and it was very difficult to control for the potentially negative effect of medication on neurocognitive function, especially as the control group was not taking any medication," Dr. Poletti and her associates noted.Read article >>
Psychiatrists are warning of the dangerous physiological impact of caffeine intoxication. An overdose of caffeine is among the mental disorders included in the latest edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) released on May 22.
Symptoms of the disorder include restlessness, nervousness, excitement, red face, gastrointestinal upset, muscle twitching, rambling speech, sleeplessness, rapid and irregular heartbeat, according to Live Science.
The findings about the mental impacts of a caffeine overdose come from the list of mental disorders compiled by the American Psychiatric Association.
The DSM is the go-to guide for a myriad of professionals seeking to understand mental disorders including physicians, psychologists, social workers, nurses, occupational and rehabilitation therapists, and counselors, according to the APA website.
Caffeine intoxication had previously been listed as a disorder but in the latest edition of the DSM, it also includes the disorder associated with caffeine withdrawal.
Symptoms of caffeine withdrawal are described as including headache, fatigue, difficulty concentrating, depressed mood and other issues.
'Caffeine is invading our society more and more,' Alan Budney, who served on the DSM-5 working group for substance-use disorders, previously told Medscape Medical News in 2011 about why caffeine withdrawal was an important disorder to investigate.
'There's concern enough to consider this topic seriously, even though it's probably one of the more controversial issues faced by our work group,' he added.
Caffeine is considered the most widely used, behaviorally active drug in the world, alongside other chemicals that can prompt mental disorders.
The other powerful chemicals include alcohol, nicotine, cannabis, hallucinogens and other mind-altering substances.Read article >>
If you sat awake last night dreading work this morning, then new research shows you are not alone.
A study has shown that two thirds of workers suffer from Sunday blues because they cannot face the thought of going into work the following day.
It also found that women are more likely to experience the phenomenon, with 71 per cent of those surveyed saying the thought of going back to work made them nervous, compared with 62 per cent of men.
The poll of more than 700 full time workers in the UK also found that half of women said they eat comfort food and one third reported drinking alcohol at home to help lift their mood.
The problem was worse among the younger generation, where three quarters of 25 to 34-year-olds said they suffered from the Sunday blues.
More than one third of this age group said they had to give themselves a pep talk to get themselves in the right mindset to face Monday at work.
Mental health charity Mind commissioned the research as it prepares for its national fundraising day Happy Monday on March 10.
The poll also revealed that one in five full time workers have made an excuse not to go into work on a Monday in the last 12 months.
One quarter admit they hate Monday because they hate their job while for one in three it is because Monday is the most stressful day of the week.
Of those who make it to work on a Monday, nearly half avoid working with one in ten 25 to 34 year olds spending between one and two hours checking personal emails and social media.
One in six of all full time workers questioned admit to buying themselves a small treat to make themselves feel happier on a Monday.
Three quarters of those aged 25 to 34 said they suffered, and a third coped by giving themselves a pep talk.Read article >>